The global Nucleic Acid And Gene Therapies In Neuromuscular Disorders market size is expected to be valued at US$ 7.88 Billion in 2023. With the increasing high incidence of cancer and other target diseases, the overall demand for Nucleic Acid And Gene Therapies In Neuromuscular Disorders is projected to grow at a CAGR of 9.5% …
Category Archives: Healthcare Trends
Advanced Therapy Medicinal Products Market | Bluebird Bio, Inc., Novartis AG, UniQure N.V., Celgene Corporation | By 2032
According to a recently published analytical report by Future Market Insights, the global Advanced Therapy Medicinal Products Market had US$ 8.7 billion in sales in 2021. The market is anticipated to grow at a 15% CAGR from 2022 to 2032, reaching a US$ 39 billion valuation. The market segment expected to generate the highest revenue …
Age Related Vision Dysfunction Industry Worth to reach US$ 130 Billion by 2033; growing at a 3.7% CAGR in the Forthcoming Decade: FMI
A recently published study by FMI expects the global Age Related Vision Dysfunction Market to augment at a 3.7% CAGR from 2023 to 2033. By the end of the said assessment period, a valuation of US$ 130 Billion is expected for the market. The rising incidence of visual impairment and blindness is a primary driver …
Mesotherapy Market is projected to increase at a CAGR of around 17.5% from 2022 to 2032
According to Future Market Insights’ Mesotherapy Market Analysis study, global mesotherapy market sales in 2021 would be US$ 134.2 Mn. The market is expected to reach a valuation of US$ 768 Mn by 2032, with a CAGR of 17.5% between 2022 and 2032. Mesotherapy Solutions is forecast to be the most profitable market, with a CAGR of …
Vernal Keratoconjunctivitis Market is expected to accumulate a value of US$ 782.42 Million by registering a CAGR of 6%
The global Vernal Keratoconjunctivitis Market is expected to garner a market value of US$ 436.9 Million in 2023 and is expected to accumulate a market value of US$ 782.42 Million by registering a CAGR of 6% in the forecast period 2023-2033. One of the reasons driving the global market over the projection period is the …
Biopsy Guidance System Market is projected to reach US$ 2 Billion by 2032 at a CAGR of 5.8%
The global Biopsy Guidance System Market is anticipated to create an opulent growth outlook of the market over the assessment period by registering a CAGR of 5.8% from 2022 to 2032. The global market was valued at US$ 1.1 Billion in 2021 and is expected to surpass a valuation of US$ 2 Billion by 2032. …
Rare NGR1 Fusion Market is likely to reach US$ 20 Billion by 2033, with a CAGR of 7.73%
The global Rare NGR1 Fusion Market is estimated to achieve an amazing valuation of US$ 9.49 billion in 2023 and reach US$ 20 billion by 2033, with a CAGR of 7.73%. With the latest insights and statistics from the biggest pharmaceutical and healthcare device manufacturers across the globe, FMI presents an extensive analysis on Rare NGR1 Fusion market. FMI offers insights into …
Primary Sclerosing Cholangitis (PSC) Market is projected to grow at a CAGR of 7.6%, totaling around US$ 314.26 Million by 2033
The global Primary Sclerosing Cholangitis (PSC) Market is expected to be worth US$ 151.07 million in 2023. Because of rising alcohol consumption, the overall demand for Primary Sclerosing Cholangitis (PSC) is expected to grow at a CAGR of 7.6% between 2023 and 2033, totaling around US$ 314.26 Million by 2033. The Primary Sclerosing Cholangitis (PSC) …
Amyotrophic Lateral Sclerosis is expected to accumulate a market value of US$ 1332.22 Million by registering a CAGR of 6% 2023 to 2033
The global Amyotrophic Lateral Sclerosis Market is estimated to generate a market value of US$ 743.90 Million in 2023 and a market value of US$ 1332.22 Million by achieving a CAGR of 6% between 2023 and 2033. Amyotrophic Lateral Sclerosis market growth can be attributable to an aging population, increased awareness of ALS, and an increasing incidence rate. Amyotrophic Lateral Sclerosis (ALS) market …
Drug-Induced Dyskinesia Market is expected to grow at a steady 4.25% CAGR, reaching a value of US$ 620.2 Million by 2033
In the year 2022, the global Drug-Induced Dyskinesia Market was estimated to be worth US$ 382 Million. Considering the rising demand in the global market, it is predicted to reach a valuation of US$ 399.8 Million by 2023. The market will also exhibit a steady CAGR of 4.25% from 2023-2033 and hence ultimately reach US$ 620.2 Million …